New lupus drug CUG252 passes first safety check in small trial
NCT ID NCT05866861
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested the safety of a new drug, CUG252, in 40 adults with mild-to-moderate systemic lupus erythematosus (SLE). Participants received multiple doses of the drug or a placebo by injection. The main goal was to see if the drug is safe and tolerable, and to understand how it moves through the body. The study is complete, but results are not yet available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CUG252
What this could lead to
If safe and effective, CUG252 could offer a new treatment option to control lupus symptoms.
What could go wrong
This is an early Phase 1 safety study with only 40 people. It is not designed to prove effectiveness, and many drugs fail at this stage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Site 1001
Anniston, Alabama, 36207, United States
-
Site 1002
Clearwater, Florida, 33765, United States
-
Site 1003
Duncansville, Pennsylvania, 16635, United States
-
Site 1004
Mesquite, Texas, 75150, United States
-
Site 1005
Middleburg Heights, Ohio, 44130, United States
-
Site 1006
Dallas, Texas, 75231, United States
-
Site 1007
Lawrenceville, Georgia, 30046, United States
-
Site 1009
Tampa, Florida, 33606, United States
-
Site 1010
Columbus, Ohio, 44106, United States
-
Site 1011
La Jolla, California, 92037, United States
-
Site 1012
Seattle, Washington, 98195, United States